野村发表研究报告,预测康方生物(09926.HK) 2026年上半年收入按年增长68%至24亿元人民币,其中药物销售贡献22亿元人民币,按年升55%,当中核心产品卡度尼利及依沃西销售预料持续增长。上半年净利润预测达到4,600万元人民币,对比2025年上半年亏损5.7亿元人民币,由亏转盈。野村认为,HARMONi-3数据发布及美国食品药品监督管理局处方药使用者收费法案(PDUFA)决定,将会是...
Source Link野村发表研究报告,预测康方生物(09926.HK) 2026年上半年收入按年增长68%至24亿元人民币,其中药物销售贡献22亿元人民币,按年升55%,当中核心产品卡度尼利及依沃西销售预料持续增长。上半年净利润预测达到4,600万元人民币,对比2025年上半年亏损5.7亿元人民币,由亏转盈。野村认为,HARMONi-3数据发布及美国食品药品监督管理局处方药使用者收费法案(PDUFA)决定,将会是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.